NOVO B Novo Nordisk A/S Class B

Novo Nordisk A/S - Share repurchase programme

Novo Nordisk A/S - Share repurchase programme

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 1 July 2019 – On 7 May 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2019.

Under the programme initiated 7 May 2019, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 8 May 2019 to 7 August 2019.

Since the announcement as of 24 June 2019, the following transactions have been made under the programme:

 Number of

B shares		Average

purchase price		Transaction

value, DKK
Accumulated, last announcement3,843,000 1,255,256,544
24 June 2019125,000332.9441,617,055
25 June 2019125,000334.9241,865,163
26 June 2019125,000336.7242,089,417
27 June 2019125,000333.2241,652,206
28 June 2019125,000334.5241,815,478
Accumulated under the programme4,468,000 1,464,295,863

The details for each transaction made under the share repurchase programme are published on .

With the transactions stated above, Novo Nordisk owns a total of 26,811,143 B shares of DKK 0.20, corresponding to 1.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2019. As of 28 June 2019, Novo Nordisk has since 1 February 2019 repurchased a total of 19,644,504 B shares at an average share price of DKK 325.75 per B share equal to a transaction value of DKK 6,399,249,464.

Further information

Media:  
Anne Margrethe Hauge
Ken Inchausti (US)
   
Investors:  
Peter Hugreffe Ankersen
Valdemar Borum Svarrer
Ann Søndermølle Rendbæk
Kristoffer Due Berg (US)
   

Company announcement No 39/2019

Attachment

EN
01/07/2019

Underlying

NOVO BNovo Nordisk A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novo Nordisk A/S Class B

Free Trial
NOVO B Novo Nordisk A/...

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS bought 6,450 shares at 312.500DKK and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

NOVO B NOVO NORDISK A/S CLASS B
11/17/25 November 17, 2025 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Zealand Pharma (Buy, TP: DKK950.00) - Dapiglutide likely next catalyst

Q1 revenue missed expectations on lower reimbursement revenue, while operating profit was a beat, as opex was below our forecast and consensus. The 2025 guidance was maintained for opex of DKK2,000m–2,500m. We believe the next potential share-price catalyst is the top-line results from the phase Ib dapiglutide trial in Q2e. We reiterate our BUY, but have cut our target price to DKK950 (1,000).

NOVO B NOVO NORDISK A/S CLASS B
05/08/25 May 8, 2025 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Novo Nordisk (Buy, TP: DKK900.00) - Accelerated Wegovy roll-out ahead

Q1 LCY figures beat our forecasts, while the 2025 guidance was cut to 13–21% LCY sales growth YOY and 16–24% LCY operating profit growth YOY due to weaker GLP-1 sales. We have lowered our rebate for US Ozempic but maintain our 52% Wegovy rebate (in line with the Q1 rebate when adjusting for de-stocking). We reiterate our BUY and DKK900 target price.

NOVO B NOVO NORDISK A/S CLASS B
05/07/25 May 7, 2025 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Novo Nordisk (Buy, TP: DKK900.00) - Underlying soft GLP-1 sales

We forecast a soft Q1, with 17.3% LCY sales growth and 13.8% LCY operating profit growth due to subdued prescriptions. While we estimate Ozempic sales c0.5% below consensus, we are c1.2% above for Wegovy, as we include DKK1bn in sales related to Wegovy US inventories. We see likely relief from potential unchanged 2025 LCY guidance, supported by improved Wegovy supply and fading pressure from compounders. We reiterate our BUY and DKK900 target price.

NOVO B NOVO NORDISK A/S CLASS B
05/01/25 May 1, 2025 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Zealand Pharma (Buy, TP: DKK1000.00) - Focus on pipeline progression

We expect an uneventful Q1 report, with investor focus on top-line results from the dapiglutide phase Ib obesity trial (due in Q2), which could help provide clarity on the positioning of the molecule in obesity and inflammation. For petrelintide, we have reduced our peak sales forecast to cUSD10.0bn (cUSD10.8bn) on increased competition from GUBamy. We reiterate our BUY but have cut our target price to DKK1,000 (1,150).

NOVO B NOVO NORDISK A/S CLASS B
04/30/25 April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch